Dear Reader,

Current treatments of overactive bladder disease (OAB) with oral medications show high discontinuation rates due to significant side effects and/or limited efficacy.
Based on the need for more effective medicines to treat OAB we have developed a proprietary dissolvable ovulum based on the work of Prof. Grant S. Mulholland, that allows the local administration of drugs through the epithelium of urethra of women. With this survey we would like to assess clinicians’ and patients’ view on the use of such a dissolvable, urethral ovulum for OAB.

We would be very grateful if you could dedicate 5-7 minutes of your time to answer the following questions.